0001214659-18-001631.txt : 20180227 0001214659-18-001631.hdr.sgml : 20180227 20180227180014 ACCESSION NUMBER: 0001214659-18-001631 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180223 FILED AS OF DATE: 20180227 DATE AS OF CHANGE: 20180227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BAUM CHARLES M CENTRAL INDEX KEY: 0001579824 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35921 FILM NUMBER: 18646869 MAIL ADDRESS: STREET 1: C/O MIRATI THERAPEUTICS INC. STREET 2: 9393 TOWNE CENTRE DRIVE, STE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mirati Therapeutics, Inc. CENTRAL INDEX KEY: 0001576263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462693615 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-332-3410 MAIL ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 marketforms-41119.xml PRIMARY DOCUMENT X0306 4 2018-02-23 0001576263 Mirati Therapeutics, Inc. MRTX 0001579824 BAUM CHARLES M C/O MIRATI THERAPEUTICS INC. 9393 TOWNE CENTRE DRIVE, STE 200 SAN DIEGO CA 92121 true true false false President & CEO Common Stock 2018-02-23 4 M false 51810 8.5 A 100366 D Common Stock 2018-02-23 4 S false 40748 27.8922 D 59618 D Common Stock 2018-02-23 4 S false 11062 28.5578 D 50932 D Common Stock 8.50 2018-02-23 4 M false 51810 0 D 2020-07-16 Common Stock 51810 155430 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017. This transaction was executed in multiple trades at prices ranging from $27.45 to $28.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $28.45 to $28.725. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. 20% of the shares subject to the stock option vested and became exercisable on the Date of Grant and 20% of the shares vested on each of the 1st 2nd, 3rd and 4th anniversaries of November 12, 2012. The options expire on July 16, 2020. Includes 2,376 shares acquired under the ESPP Purchase on 11/30/17. /s/ Vickie Reed, Attorney-in-Fact 2018-02-27